Exercise and levodopa metabolism in Parkinson disease
Objective: The aim of our paper was to assess if standard physical exercise may change pharmacokinetics of levodopa/benserazide in patients with and without prior exposure…Real-World Utilization of Istradefylline Among Patients with Parkinson’s Disease
Objective: This study examined real-world utilization of istradefylline and other PD-related medications before and after istradefylline initiation. Background: Istradefylline is indicated as adjunctive therapy to…Understanding patient perceptions of advanced Parkinson’s disease (aPD) treatments
Objective: To explore patients’ perceptions of treatment options for aPD and treatment decision considerations. Background: As PD advances, some people with Parkinson’s (PwP) on oral…Alopecia in females with young onset Parkinson’s Disease: an exploratory survey
Objective: To explore the symptoms of females with young onset Parkinson's Disease (YOPD), specifically alopecia, in comparison to females with traditional onset Parkinson’s Disease (TOPD).…The mGlu2 positive allosteric modulator AZD8529 alleviates L-DOPA-induced dyskinesia and psychosis-like behaviours in the parkinsonian marmoset
Objective: To assess the effect of the metabotropic glutamate 2 (mGlu2) receptor positive allosteric modulator (PAM) AZD8529 on L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia and psychosis-like behaviours (PLBs)…Clinical analysis of Levodopa/carbidopa intestinal gel infusion in advanced Parkinson’s disease. A single-center retrospective cohort study.
Objective: To evaluate clinical impact of treatment (LCIG) infusion in patients with advanced PD. Background: Levodopa/carbidopa intestinal gel (LCIG) infusion has demonstrated more stable plasma…Integrated analysis of phase 3 trials of foslevodopa/foscarbidopa demonstrated that majority of reported infusion site AEs including infections were non serious, mild to moderate in severity and did not result in treatment discontinuation.
Objective: To characterize reported infusion site infection adverse events (AEs) and their clinical management in patients with Parkinson’s disease (PD) treated with foslevodopa/foscarbidopa (LDP/CDP). Background:…Pharmacological combinations in early stages of Parkinson’s disease and association with motor complications
Objective: To describe the different combinations of dopaminergic drugs at the early stage of Parkinson’s disease (PD) in a real-life cohort, and to determine their…Quetiapine for the treatment of psychosis in dementia with Lewy bodies: a systematic review.
Objective: Perform a systematic review of the literature about the efficacy of quetiapine in the treatment of psychosis in patients with Lewy’s Body Dementia. Background:…Bowel symptoms and management practices in Parkinson’s disease and related conditions: results from the PRIME-UK study.
Objective: To describe bowel symptoms and constipation management practices in a large, representative cross-sectional study of Parkinson’s and related disorders. Background: Bowel symptoms, particularly constipation,…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 34
- Next Page »